Review article

The global emergence of Helicobacter pylori antibiotic resistance

I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek

Research output: Contribution to journalReview article

185 Citations (Scopus)

Abstract

Background Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma. Aim To review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms. Methods A PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing. Results The prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15%; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced. Conclusions Since the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.

Original languageEnglish (US)
Pages (from-to)514-533
Number of pages20
JournalAlimentary Pharmacology and Therapeutics
Volume43
Issue number4
DOIs
StatePublished - Feb 1 2016

Fingerprint

Microbial Drug Resistance
Helicobacter pylori
Clarithromycin
Anti-Bacterial Agents
Bacterial Drug Resistance
Levofloxacin
Gastrointestinal Diseases
Metronidazole
Therapeutics
Turkey
Treatment Failure
Peptic Ulcer
Taiwan
PubMed
Sweden
Italy
China
Stomach
Japan
Carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Review article : The global emergence of Helicobacter pylori antibiotic resistance. / Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J. Y.; Crowe, S. E.; Valasek, M. A.

In: Alimentary Pharmacology and Therapeutics, Vol. 43, No. 4, 01.02.2016, p. 514-533.

Research output: Contribution to journalReview article

Thung, I, Aramin, H, Vavinskaya, V, Gupta, S, Park, JY, Crowe, SE & Valasek, MA 2016, 'Review article: The global emergence of Helicobacter pylori antibiotic resistance', Alimentary Pharmacology and Therapeutics, vol. 43, no. 4, pp. 514-533. https://doi.org/10.1111/apt.13497
Thung, I. ; Aramin, H. ; Vavinskaya, V. ; Gupta, S. ; Park, J. Y. ; Crowe, S. E. ; Valasek, M. A. / Review article : The global emergence of Helicobacter pylori antibiotic resistance. In: Alimentary Pharmacology and Therapeutics. 2016 ; Vol. 43, No. 4. pp. 514-533.
@article{80a7b1878ab44eb2b9450700330bbfc6,
title = "Review article: The global emergence of Helicobacter pylori antibiotic resistance",
abstract = "Background Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma. Aim To review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms. Methods A PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing. Results The prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30{\%} in Japan and Italy, 50{\%} in China and 40{\%} in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15{\%}; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced. Conclusions Since the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.",
author = "I. Thung and H. Aramin and V. Vavinskaya and S. Gupta and Park, {J. Y.} and Crowe, {S. E.} and Valasek, {M. A.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/apt.13497",
language = "English (US)",
volume = "43",
pages = "514--533",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Review article

T2 - The global emergence of Helicobacter pylori antibiotic resistance

AU - Thung, I.

AU - Aramin, H.

AU - Vavinskaya, V.

AU - Gupta, S.

AU - Park, J. Y.

AU - Crowe, S. E.

AU - Valasek, M. A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma. Aim To review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms. Methods A PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing. Results The prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15%; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced. Conclusions Since the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.

AB - Background Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma. Aim To review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms. Methods A PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing. Results The prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15%; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced. Conclusions Since the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient-specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.

UR - http://www.scopus.com/inward/record.url?scp=84954362099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954362099&partnerID=8YFLogxK

U2 - 10.1111/apt.13497

DO - 10.1111/apt.13497

M3 - Review article

VL - 43

SP - 514

EP - 533

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -